APO RESEARCH · REPORT
Inosine Pranobex
Inosine pranobex (BAN; also known as inosine acedoben dimepranol (INN) or methisoprinol) an antiviral drug that is a combination of inosine and dimepranol acedoben (a salt of acetamidobenzoic acid and dimethylaminoisopropanol) in a ratio of 1 to 3. Inosine pranobex has no effect on viral particles itself. Instead, it acts as an immunostimulant, an analog of thymus hormones. It is most commonly used to treat the rare measles complication subacute sclerosing panencephalitis in conjunction with intrathecal interferon therapy.
Product & engineering
Understand the product.
Inosine pranobex (BAN; also known as inosine acedoben dimepranol (INN) or methisoprinol) an antiviral drug that is a combination of inosine and dimepranol acedoben (a salt of acetamidobenzoic acid and dimethylaminoisopropanol) in a ratio of 1 to 3. Inosine pranobex has no effect on viral particles itself. Instead, it acts as an immunostimulant, an analog of thymus hormones. It is most commonly used to treat the rare measles complication subacute sclerosing panencephalitis in conjunction with intrathecal interferon therapy.
Selected research
Industry Research
Inosine Pranobex Industry Research Report 2026
Market perspective
Inosine pranobex (BAN; also known as inosine acedoben dimepranol (INN) or methisoprinol) an antiviral drug that is a combination of inosine and dimepranol acedoben (a salt of acetamidobenzoic acid and dimethylaminoisopropanol) in a ratio of 1 to 3. Inosine pranobex has no effect on viral particles itself. Instead, it acts as an immunostimulant, an analog of thymus hormones. It is most commonly used to treat the rare measles complication subacute sclerosing panencephalitis in conjunction with intrathecal interferon therapy.
Global Inosine Pranobex key players include Newport Pharmaceuticals, Gedeon Richter, etc. Global top two manufacturers hold a share about 50%.
Europe is the largest market, with a share about 55%, followed by North America and Japan, both have a share about 20 percent.
Read the full market overview
In terms of product, Tablet is the largest segment, with a share about 70%. And in terms of application, the largest application is Antiviral, followed by Immunomodulation, etc.
Report Scope
This report quantifies the global Inosine Pranobex market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Inosine Pranobex Market by Company
Newport Pharmaceuticals
Gedeon Richter
Mochida
Sanofi
Andrómaco
Yung Shin
Alfasigma S.p.A.
Polfarmex
Sanfer
Meprofarm
Novell Pharmaceutical
Aflofarm
Inosine Pranobex Segment by Type
Tablet
Syrup
Inosine Pranobex Segment by Application
Immunomodulation
Antiviral
Other
Inosine Pranobex Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Inosine Pranobex market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Inosine Pranobex and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Inosine Pranobex.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Inosine Pranobex manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Inosine Pranobex by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Inosine Pranobex in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Tablet
- Syrup
Applications
- Immunomodulation
- Antiviral
- Other
Companies covered
- Newport Pharmaceuticals
- Gedeon Richter
- Mochida
- Sanofi
- Andrómaco
- Yung Shin
- Alfasigma S.p.A.
- Polfarmex
- Sanfer
- Meprofarm
- Novell Pharmaceutical
- Aflofarm
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Inosine Pranobex Market Size (2021-2032)
- 2.2.2 Global Inosine Pranobex Sales (2021-2032)
- 2.2.3 Global Inosine Pranobex Market Average Price (2021-2032)
- 2.3 Inosine Pranobex by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Tablet
- 2.3.3 Syrup
- 2.4 Inosine Pranobex by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Immunomodulation
- 2.4.3 Antiviral
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Inosine Pranobex Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Inosine Pranobex Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Inosine Pranobex Revenue of Manufacturers (2021-2026)
- 3.4 Global Inosine Pranobex Average Price by Manufacturers (2021-2026)
- 3.5 Global Inosine Pranobex Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Inosine Pranobex, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Inosine Pranobex, Product Type & Application
- 3.8 Global Manufacturers of Inosine Pranobex, Established Date
- 3.9 Global Inosine Pranobex Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Newport Pharmaceuticals
- 4.1.1 Newport Pharmaceuticals Company Information
- 4.1.2 Newport Pharmaceuticals Business Overview
- 4.1.3 Newport Pharmaceuticals Inosine Pranobex Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Newport Pharmaceuticals Inosine Pranobex Product Portfolio
- 4.1.5 Newport Pharmaceuticals Recent Developments
- 4.2 Gedeon Richter
- 4.2.1 Gedeon Richter Company Information
- 4.2.2 Gedeon Richter Business Overview
- 4.2.3 Gedeon Richter Inosine Pranobex Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Gedeon Richter Inosine Pranobex Product Portfolio
- 4.2.5 Gedeon Richter Recent Developments
- 4.3 Mochida
- 4.3.1 Mochida Company Information
- 4.3.2 Mochida Business Overview
- 4.3.3 Mochida Inosine Pranobex Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Mochida Inosine Pranobex Product Portfolio
- 4.3.5 Mochida Recent Developments
- 4.4 Sanofi
- 4.4.1 Sanofi Company Information
- 4.4.2 Sanofi Business Overview
- 4.4.3 Sanofi Inosine Pranobex Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Sanofi Inosine Pranobex Product Portfolio
- 4.4.5 Sanofi Recent Developments
- 4.5 Andrómaco
- 4.5.1 Andrómaco Company Information
- 4.5.2 Andrómaco Business Overview
- 4.5.3 Andrómaco Inosine Pranobex Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Andrómaco Inosine Pranobex Product Portfolio
- 4.5.5 Andrómaco Recent Developments
- 4.6 Yung Shin
- 4.6.1 Yung Shin Company Information
- 4.6.2 Yung Shin Business Overview
- 4.6.3 Yung Shin Inosine Pranobex Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Yung Shin Inosine Pranobex Product Portfolio
- 4.6.5 Yung Shin Recent Developments
- 4.7 Alfasigma S.p.A.
- 4.7.1 Alfasigma S.p.A. Company Information
- 4.7.2 Alfasigma S.p.A. Business Overview
- 4.7.3 Alfasigma S.p.A. Inosine Pranobex Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Alfasigma S.p.A. Inosine Pranobex Product Portfolio
- 4.7.5 Alfasigma S.p.A. Recent Developments
- 4.8 Polfarmex
- 4.8.1 Polfarmex Company Information
- 4.8.2 Polfarmex Business Overview
- 4.8.3 Polfarmex Inosine Pranobex Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Polfarmex Inosine Pranobex Product Portfolio
- 4.8.5 Polfarmex Recent Developments
- 4.9 Sanfer
- 4.9.1 Sanfer Company Information
- 4.9.2 Sanfer Business Overview
- 4.9.3 Sanfer Inosine Pranobex Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Sanfer Inosine Pranobex Product Portfolio
- 4.9.5 Sanfer Recent Developments
- 4.10 Meprofarm
- 4.10.1 Meprofarm Company Information
- 4.10.2 Meprofarm Business Overview
- 4.10.3 Meprofarm Inosine Pranobex Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Meprofarm Inosine Pranobex Product Portfolio
- 4.10.5 Meprofarm Recent Developments
- 4.11 Novell Pharmaceutical
- 4.11.1 Novell Pharmaceutical Company Information
- 4.11.2 Novell Pharmaceutical Business Overview
- 4.11.3 Novell Pharmaceutical Inosine Pranobex Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Novell Pharmaceutical Inosine Pranobex Product Portfolio
- 4.11.5 Novell Pharmaceutical Recent Developments
- 4.12 Aflofarm
- 4.12.1 Aflofarm Company Information
- 4.12.2 Aflofarm Business Overview
- 4.12.3 Aflofarm Inosine Pranobex Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Aflofarm Inosine Pranobex Product Portfolio
- 4.12.5 Aflofarm Recent Developments
5 Global Inosine Pranobex Market Scenario by Region
- 5.1 Global Inosine Pranobex Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Inosine Pranobex Sales by Region: 2021-2032
- 5.2.1 Global Inosine Pranobex Sales by Region: 2021-2026
- 5.2.2 Global Inosine Pranobex Sales by Region: 2027-2032
- 5.3 Global Inosine Pranobex Revenue by Region: 2021-2032
- 5.3.1 Global Inosine Pranobex Revenue by Region: 2021-2026
- 5.3.2 Global Inosine Pranobex Revenue by Region: 2027-2032
- 5.4 North America Inosine Pranobex Market Facts & Figures by Country
- 5.4.1 North America Inosine Pranobex Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Inosine Pranobex Sales by Country (2021-2032)
- 5.4.3 North America Inosine Pranobex Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Inosine Pranobex Market Facts & Figures by Country
- 5.5.1 Europe Inosine Pranobex Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Inosine Pranobex Sales by Country (2021-2032)
- 5.5.3 Europe Inosine Pranobex Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Inosine Pranobex Market Facts & Figures by Country
- 5.6.1 Asia Pacific Inosine Pranobex Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Inosine Pranobex Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Inosine Pranobex Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Inosine Pranobex Market Facts & Figures by Country
- 5.7.1 South America Inosine Pranobex Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Inosine Pranobex Sales by Country (2021-2032)
- 5.7.3 South America Inosine Pranobex Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Inosine Pranobex Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Inosine Pranobex Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Inosine Pranobex Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Inosine Pranobex Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Inosine Pranobex Sales by Type (2021-2032)
- 6.1.1 Global Inosine Pranobex Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Inosine Pranobex Sales Market Share by Type (2021-2032)
- 6.2 Global Inosine Pranobex Revenue by Type (2021-2032)
- 6.2.1 Global Inosine Pranobex Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Inosine Pranobex Revenue Market Share by Type (2021-2032)
- 6.3 Global Inosine Pranobex Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Inosine Pranobex Sales by Application (2021-2032)
- 7.1.1 Global Inosine Pranobex Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Inosine Pranobex Sales Market Share by Application (2021-2032)
- 7.2 Global Inosine Pranobex Revenue by Application (2021-2032)
- 7.2.1 Global Inosine Pranobex Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Inosine Pranobex Revenue Market Share by Application (2021-2032)
- 7.3 Global Inosine Pranobex Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Inosine Pranobex Value Chain Analysis
- 8.1.1 Inosine Pranobex Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Inosine Pranobex Production Mode & Process
- 8.2 Inosine Pranobex Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Inosine Pranobex Distributors
- 8.2.3 Inosine Pranobex Customers
9 Global Inosine Pranobex Analyzing Market Dynamics
- 9.1 Inosine Pranobex Industry Trends
- 9.2 Inosine Pranobex Industry Drivers
- 9.3 Inosine Pranobex Industry Opportunities and Challenges
- 9.4 Inosine Pranobex Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst